NASDAQ:SBTX Silverback Therapeutics (SBTX) Stock Price, News & Analysis $12.83 +0.03 (+0.23%) As of 04/7/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock About Silverback Therapeutics Stock (NASDAQ:SBTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SBTX alerts:Sign Up Key Stats Today's Range$12.00▼$13.7950-Day Range$10.18▼$14.8852-Week Range$2.80▼$8.97Volume2.98 million shsAverage Volume337,931 shsMarket Capitalization$462.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSilverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Read More… Remove Ads Receive SBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SBTX Stock News HeadlinesARS Pharmaceuticals Inc (SPRY)May 11, 2023 | uk.investing.comSPRY ARS Pharmaceuticals, Inc.January 24, 2023 | seekingalpha.comElon’s 2025 Silver Crisis (What It Means for You)Silver isn't just a safe haven for your wealth—it's a critical resource in the global tech and energy race. With Elon Musk leading the charge, supplies are vanishing fast. Don't wait until it's out of reach.April 8, 2025 | GoldenCrest Metals (Ad)ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After MergerNovember 22, 2022 | 247wallst.comDr. Sarina Tanimoto Discloses Position in SBTX / Silverback TherapeuticsNovember 18, 2022 | nasdaq.comARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNovember 10, 2022 | finance.yahoo.comARS Pharmaceuticals Closes Merger with Silverback TherapeuticsNovember 8, 2022 | finance.yahoo.comSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic ReactionsOctober 28, 2022 | markets.businessinsider.comSee More Headlines SBTX Stock Analysis - Frequently Asked Questions How have SBTX shares performed this year? Silverback Therapeutics' stock was trading at $10.55 at the beginning of 2025. Since then, SBTX stock has increased by 21.6% and is now trading at $12.83. View the best growth stocks for 2025 here. How were Silverback Therapeutics' earnings last quarter? Silverback Therapeutics, Inc. (NASDAQ:SBTX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.65) earnings per share for the quarter, meeting the consensus estimate of ($0.65). When did Silverback Therapeutics IPO? Silverback Therapeutics (SBTX) raised $126 million in an IPO on Friday, December 4th 2020. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, SVB Leerink and Stifel served as the underwriters for the IPO and H.C. Wainwright was co-manager. How do I buy shares of Silverback Therapeutics? Shares of SBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Silverback Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Silverback Therapeutics investors own include Athenex (ATNX), AbbVie (ABBV), Applied Materials (AMAT), JPMorgan Chase & Co. (JPM), Luminar Technologies (LAZR), Lineage Cell Therapeutics (LCTX) and Aviat Networks (AVNW). Company Calendar Last Earnings11/10/2021Today4/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SBTX CIK1671858 Webwww.silverbacktx.com Phone206 456 2900FaxN/AEmployees83Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.62% Return on Assets-28.20% Debt Debt-to-Equity RatioN/A Current Ratio67.87 Quick Ratio67.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.41 per share Price / Book1.73Miscellaneous Outstanding Shares36,058,000Free Float23,654,000Market Cap$461.54 million OptionableNot Optionable Beta0.60 20 Stocks to Sell NowGet This Free Report This page (NASDAQ:SBTX) was last updated on 4/8/2025 by MarketBeat.com Staff From Our PartnersElon’s 2025 Silver Crisis (What It Means for You)Silver isn't just a safe haven for your wealth—it's a critical resource in the global tech and energy race. Wi...GoldenCrest Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | Sponsored**Breaking NEWS* This Company Starts To Rally As it Reduces $20 Million in Debt**Breaking NEWS* This Company Starts To Rally As it Reduces $20 Million in Debt Discover why Notable Names ...Huge Alerts | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredWill the U.S. military protect this $10B gold mine?You don’t need the gold price to move another inch for this company to potentially re-rate several hundred per...Golden Portfolio | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silverback Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.